CytomX Therapeutics (NASDAQ:CTMX) Upgraded at Piper Sandler

Piper Sandler upgraded shares of CytomX Therapeutics (NASDAQ:CTMX – Free Report) from a neutral rating to an overweight rating in a report published on Tuesday morning, MarketBeat.com reports. Piper Sandler currently has $3.50 price objective on the biotechnology company’s stock, up from their prior price objective of $2.25. A number of other research firms have […]

Related Keywords

Piper Sandler ,Seana Mccarthy ,Jpmorgan Chase Co ,Congress Park Capital ,Alphamark Advisors ,Jefferies Financial Group ,Acadian Asset Management ,Sg Americas Securities ,Susquehanna Fundamental Investments ,Cytomx Therapeutics Inc ,Cytomx Therapeutics Company Profile ,Securities Exchange Commission ,Cytomx Therapeutics ,Free Report ,Financial Group ,Moderate Buy ,Get Free Report ,Exchange Commission ,Mark Advisors ,Asset Management ,Fundamental Investments ,Spark Capital ,Cytomx Therapeutics Daily ,